vs
Side-by-side financial comparison of Net Lease Office Properties (NLOP) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Net Lease Office Properties is the larger business by last-quarter revenue ($30.7M vs $18.6M, roughly 1.6× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -0.2%, a 65.9% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 10.9%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -16.4%).
Net Lease Office Properties is a real estate investment entity focused on acquiring, owning, and operating high-quality single-tenant net lease office assets, primarily located across the United States. It delivers stable, long-term income streams to investors through its curated portfolio of commercial real estate holdings.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
NLOP vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.7M | $18.6M |
| Net Profit | $-53.0K | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -0.2% | 56.3% |
| Net Margin | -0.2% | 65.7% |
| Revenue YoY | 10.9% | 1808.5% |
| Net Profit YoY | 99.9% | 376.5% |
| EPS (diluted) | $-0.01 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.7M | $18.6M | ||
| Q3 25 | $29.8M | $334.0K | ||
| Q2 25 | $29.2M | $1.4M | ||
| Q1 25 | $29.2M | $257.0K | ||
| Q4 24 | $27.7M | $977.0K | ||
| Q3 24 | $31.5M | $660.0K | ||
| Q2 24 | $39.0M | $736.0K | ||
| Q1 24 | $44.0M | $1.4M |
| Q4 25 | $-53.0K | $12.3M | ||
| Q3 25 | $-64.2M | $-8.6M | ||
| Q2 25 | $-81.5M | $-6.9M | ||
| Q1 25 | $492.0K | $-5.4M | ||
| Q4 24 | $-35.8M | — | ||
| Q3 24 | $-40.3M | $-2.8M | ||
| Q2 24 | $12.5M | $-14.5M | ||
| Q1 24 | $-27.8M | $411.0K |
| Q4 25 | -0.2% | 56.3% | ||
| Q3 25 | -215.2% | -2516.5% | ||
| Q2 25 | -279.1% | -701.0% | ||
| Q1 25 | 2.0% | -3350.2% | ||
| Q4 24 | -140.7% | — | ||
| Q3 24 | -126.4% | -1563.6% | ||
| Q2 24 | 32.3% | -1255.0% | ||
| Q1 24 | -62.7% | -692.5% |
| Q4 25 | -0.2% | 65.7% | ||
| Q3 25 | -215.4% | -2572.2% | ||
| Q2 25 | -279.5% | -504.8% | ||
| Q1 25 | 1.7% | -2097.7% | ||
| Q4 24 | -129.0% | — | ||
| Q3 24 | -128.0% | -425.5% | ||
| Q2 24 | 31.9% | -1964.4% | ||
| Q1 24 | -63.3% | 29.9% |
| Q4 25 | $-0.01 | $0.25 | ||
| Q3 25 | $-4.33 | $-0.17 | ||
| Q2 25 | $-5.50 | $-0.14 | ||
| Q1 25 | $0.03 | $-0.11 | ||
| Q4 24 | $-2.41 | — | ||
| Q3 24 | $-2.73 | $-0.06 | ||
| Q2 24 | $0.84 | $-0.30 | ||
| Q1 24 | $-1.88 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $119.6M | $40.0M |
| Total DebtLower is stronger | $21.9M | — |
| Stockholders' EquityBook value | $293.9M | $49.4M |
| Total Assets | $453.4M | $59.0M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $119.6M | $40.0M | ||
| Q3 25 | $38.7M | $37.9M | ||
| Q2 25 | $54.1M | $44.8M | ||
| Q1 25 | $28.2M | $40.6M | ||
| Q4 24 | $25.1M | $59.3M | ||
| Q3 24 | $36.1M | $68.8M | ||
| Q2 24 | $36.1M | $73.0M | ||
| Q1 24 | $39.8M | $80.2M |
| Q4 25 | $21.9M | — | ||
| Q3 25 | $47.1M | — | ||
| Q2 25 | $117.2M | — | ||
| Q1 25 | $148.5M | — | ||
| Q4 24 | $169.2M | — | ||
| Q3 24 | $239.4M | — | ||
| Q2 24 | $327.4M | — | ||
| Q1 24 | $515.2M | — |
| Q4 25 | $293.9M | $49.4M | ||
| Q3 25 | $430.3M | $36.4M | ||
| Q2 25 | $500.0M | $44.5M | ||
| Q1 25 | $582.1M | $50.5M | ||
| Q4 24 | $581.2M | $55.1M | ||
| Q3 24 | $621.9M | $58.5M | ||
| Q2 24 | $660.3M | $60.4M | ||
| Q1 24 | $647.2M | $74.1M |
| Q4 25 | $453.4M | $59.0M | ||
| Q3 25 | $522.6M | $51.1M | ||
| Q2 25 | $668.7M | $60.7M | ||
| Q1 25 | $784.1M | $67.9M | ||
| Q4 24 | $805.1M | $90.6M | ||
| Q3 24 | $919.9M | $99.0M | ||
| Q2 24 | $1.0B | $107.8M | ||
| Q1 24 | $1.2B | $118.3M |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.26× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.80× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $64.1M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.1M | $18.4M | ||
| Q3 25 | $16.3M | $-8.7M | ||
| Q2 25 | $11.7M | $-7.5M | ||
| Q1 25 | $14.1M | $-7.5M | ||
| Q4 24 | $71.9M | $-24.0M | ||
| Q3 24 | $20.3M | $765.0K | ||
| Q2 24 | $14.7M | $-10.9M | ||
| Q1 24 | $26.4M | $-4.0M |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 28.70× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NLOP
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
